|
Pharmaceutical Giants AstraZeneca (AZN), Rigel (RIGL) Collaborate On Arthritis Drug |
|
|
|
|
Wednesday, 17 February 2010 |
|
 As per the deal, Rigel will receive $100 million upfront with an additional $345 million if certain conditions pertaining to sales targets and development are met. AstraZeneca may also pay additional $800 million if Rigel meets certain sales-related milestones for the product called fostamatinib disodium or R788, and achieves considerable commercial success.
The companies estimated the demand for rheumatoid arthritis drug was worth around $13 billion globally last year, up from $1.3 billion in 1998. |
